Info

USBiomaterials ("USB") develops products that restore tissue structure and function, leveraging a single proprietary science platform into three different product development categories. This science platform is a series of inorganic, bioactive material formulations - composed entirely of elements naturally occurring in body chemistry -- that release ions into local body environments in concentrations needed to facilitate key biological processes at that site. The Company has already commercialized products in two of the three platforms, thereby demonstrating FDA approvability, safety and efficacy, and the Company's ability to execute its plans. This first platform is bone graft substitutes (NovaBone® and PerioGlas®) that offer a more natural regeneration response than "growth factors", but with similar stimulatory effects. The second platform spawned a new company -- NovaMin Technology Inc. -- which developing products for its second platform (NovaMinÔ) - a tooth remineralizer that is safer and works faster and in a broader range of situations than the current standard of fluoride. The Company is also planning to pursue its third platform ("CSM Technology"), which offers localized anti-inflammatory (anti-TNF) effects, with target applications for inflammatory skin conditions (i.e. psoriasis) and post-surgical inflammatory complications.